Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
16 April 2021Website:
http://www.akoyabio.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:02:33 GMTDividend
Analysts recommendations
Institutional Ownership
AKYA Latest News
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
Akoya Biosciences, Inc. (NASDAQ: AKYA) Q1 2024 Earnings Conference Call on May 13, 2024 at 5:00 PM ET with Company Participants Priyam Shah, Brian McKelligon, and Johnny Ek, as well as various Conference Call Participants. Thank you for joining the Akoya Biosciences First Quarter 2024 Earnings Conference Call.
Akoya Biosciences (AKYA) reported a quarterly loss of $0.35 per share, which was higher than the expected loss of $0.30 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.49 per share reported in the same quarter last year.
Akoya (AKYA) lacks the necessary elements for a potential earnings surprise in its upcoming report. Be ready with the key projections.
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley John Sourbeer - UBS Mark Massaro - BTIG Rachel Vatnsdal - JP Morgan Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Fourth Quarter 2023 Earnings Conference Call.
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.50 per share a year ago.
Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
Akoya Biosciences (AKYA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
The average of price targets set by Wall Street analysts indicates a potential upside of 86% in Akoya (AKYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What type of business is Akoya Biosciences?
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
What sector is Akoya Biosciences in?
Akoya Biosciences is in the Healthcare sector
What industry is Akoya Biosciences in?
Akoya Biosciences is in the Medical Instruments & Supplies industry
What country is Akoya Biosciences from?
Akoya Biosciences is headquartered in United States
When did Akoya Biosciences go public?
Akoya Biosciences initial public offering (IPO) was on 16 April 2021
What is Akoya Biosciences website?
https://www.akoyabio.com
Is Akoya Biosciences in the S&P 500?
No, Akoya Biosciences is not included in the S&P 500 index
Is Akoya Biosciences in the NASDAQ 100?
No, Akoya Biosciences is not included in the NASDAQ 100 index
Is Akoya Biosciences in the Dow Jones?
No, Akoya Biosciences is not included in the Dow Jones index
When does Akoya Biosciences report earnings?
The next expected earnings date for Akoya Biosciences is 07 August 2024